BioSpace News Archive

Senseonics Holdings, Inc. (NYSE-American: SENS) today announced the first pediatric study participant has been inserted with Eversense® 365-day system as part of the pivotal ENHANCE clinical trial at the AMCR Institute, a clinical research center focused on pre-diabetes, type 1, type 2 diabetes and obesity, under the direction of Dr. Timothy Bailey.

Everest Medicines announced that it has signed a Memorandum of Understanding for a strategic partnership with a subsidiary of Shanghai Pharma, SPH Keyuan Xinhua Pharmaceutical Co., Ltd.

Nona Biosciences announced it has entered into a collaboration agreement with Michael S. Diamond, MD, PhD, of Washington University in St. Louis to discover viral targets for which few or no human monoclonal antibodies currently exist, such as western equine encephalitis virus, rabies and severe fever with thrombocytopenia syndrome virus.

TELA Bio, Inc. announced the pricing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a price to the public of $9.50 per share, for gross proceeds of $45.125 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

EMulate Therapeutics announced that Chris Rivera will present an overview of current results and future plans for EMTx at the Life Science Innovation Northwest 2023.

BeyondSpring Inc. provided a business update and reported results for the year ended December 31, 2022.

Willow Biosciences Inc announces execution of a commercial agreement with Sandhill One, LLC.

DELFI Diagnostics, Inc. presented proof-of-concept data demonstrating how DELFI’s platform can be used for monitoring the treatment of patients with advanced cancer without requiring any prior genomic information about the patient’s tumor.

BeyondSpring Inc. announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 with the U.S. Securities and Exchange Commission on April 18, 2023.

Harvard Bioscience, Inc. announced the initial order for the Company’s new high-capacity behavioral monitoring system for pre-clinical applications.